Series C investment set to scale peptide discovery operations and expand access to sustainable healthspan solutions.
Nuritas, a Dublin-based biotech specializing in AI-driven peptide discovery, has announced the successful completion of its $42 million Series C funding round. Led by M&G Investments, through its Catalyst strategy, and with key participation from McWin Capital Partners and returning investors Grosvenor and the European Circular Bioeconomy Fund (ECBF), this investment marks a pivotal moment for the company as it seeks to expand its global footprint and accelerate its contribution to health and wellness through the development of innovative ingredients.
Founded in 2014, Nuritas uses a proprietary artificial intelligence platform, Magnifier, to uncover bioactive peptides from natural sources. Peptides – short chains of amino acids – are increasingly recognized for their potential in addressing pressing global health challenges. By analyzing vast datasets, Magnifier aims to identify peptides with specific health benefits and rapidly advance them from discovery to market. Nuritas’ platform improves ingredient discovery by reducing the time and cost associated with traditional methods, allowing the identification of compounds that would otherwise remain hidden within natural matrices. The company says its technology enables the discovery of health-promoting peptides 10-50 times faster than traditional methods, and achieves a clinical success rate of over 80%; these peptides address a broad spectrum of health concerns, ranging from muscle repair to skin health, and are integrated into functional foods, dietary supplements and therapeutic applications.
Longevity.Technology: The $42 million Series C funding secured by Nuritas is a testament to the intersection of artificial intelligence and preventative health. By leveraging its proprietary Magnifier platform, Nuritas aims to rapidly accelerate the discovery of bioactive peptides with clinically validated benefits that empower individuals to extend their healthspan through accessible, functional solutions.
The integration of artificial intelligence into ingredient innovation reflects a broader shift in how we approach health and longevity. Traditional methods of discovering functional ingredients have been slow and costly, often lagging behind the pressing health needs of modern consumers. However, advances in AI-driven platforms are accelerating the development of targeted solutions, offering the potential to address global health challenges with unprecedented efficiency. These breakthroughs mark a turning point, moving beyond reactive healthcare toward proactive strategies that prioritize healthspan and disease prevention. As the demand for personalized, science-backed nutrition grows, innovations like these are redefining the standards of preventative care and sustainable health, setting the stage for a future where technology enables people to take proactive control of their healthspan.
Dr Nora Khaldi, Founder and CEO of Nuritas, highlighted the company’s vision: “Our mission is to improve the lives of billions by creating ingredients that address pressing global health challenges. Through our science-first approach, we are fundamentally shifting the paradigm of ingredient discovery, enabling our customers to deliver healthier, differentiated products that meet the needs of today’s consumers.”
Notable peptide innovations include PeptiStrong, derived from fava beans, which supports muscle generation and repair and has been validated by three human clinical trials, and recent addition PeptiYouth, which targets skin health by promoting collagen production and reducing wrinkle depth and already features in skincare products across the US and Asia.
Scaling for global impact
The Series C funding will enable Nuritas to expand its operations and accelerate its ability to bring innovative peptide-based ingredients to a global market; the company plans to scale its production capabilities, enhance its scientific teams and deepen collaborations with existing and new partners.
Nuritas has already forged partnerships with global leaders such as Nestlé, Givaudan, Mars and Sumitomo Corporation; collaborations that demonstrate the versatility of Nuritas’ peptides across sectors including functional foods, dietary supplements, cosmetics and medical applications.
The investment will also support Nuritas’ efforts to introduce three new clinically validated peptides in 2025. These products will complement its existing portfolio and further address health challenges linked to aging populations and lifestyle-related diseases.
Leadership and strategic direction
As part of the funding round, Nuritas has welcomed two new members to its Board of Directors: Alex Seddon of M&G Investments and Henry McGovern, co-founder of McWin Capital Partners. Both bring extensive expertise in scaling high-growth companies and share Nuritas’ commitment to advancing sustainable health solutions.
Khaldi expressed enthusiasm for the new additions, stating: “We are thrilled to welcome M&G’s Catalyst team and McWin Capital Partners, who share our vision of making healthier ingredients accessible to billions of people globally. This investment, alongside the addition of experienced board members, will propel our mission to new heights.”
Sustainable solutions for global health
Nuritas emphasizes sustainability throughout its operations, using plant-based sources and minimizing waste in peptide extraction and production processes. These practices align with a growing demand for health solutions that are both effective and environmentally responsible.
The company’s commitment to innovation, coupled with its AI-driven approach, positions it as a leader in the field of ingredient discovery. As global health challenges evolve, Nuritas’ ability to rapidly develop targeted, science-backed peptides offers a promising pathway to improving the health and wellness of millions, and now with $42 million in new funding, the company looks likely to advance its mission of transforming natural compounds into impactful healthspan solutions.
